Ten studies from 2013 with potential to change endocrinology practice were summarized in Annals of Internal Medicine's annual Update in Endocrinology, published in the June 3 issue.
Sodium-glucose cotransporter-2 (SGLT2) inhibitors were associated with fewer hospitalizations for heart failure and slower progression of kidney disease while glucagon-like peptide-1 (GLP-1) receptor agonists were associated with lower risk of stroke
A recent scientific statement on diabetes and heart failure summarizes the epidemiology, pathophysiology, and impact of diabetes on outcomes in heart failure; reviews pharmacological therapy and lifestyle modification; highlights the value
They pointed out that almost 50% of patients with diabetes have severe periodontitis and that their findings“ highlight the potential to improve metabolic control and possibly diabetes outcomes by addressing poor
The updates were based on findings from the industry-funded CREDENCE (Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy) trial.
An analysis of patients with insulin-treated diabetes found that 38% of those with late-onset type 1 diabetes did not receive insulin at diagnosis, nearly half of whom reported a type 2 diabetes diagnosis.
Other independent predictors of long-term weight loss included greater weight loss in the first year and older age, according to this follow-up analysis of the Diabetes Prevention Program.
Compared to young adults without diabetes, those with diabetes were more likely to have obesity, elevated lipids, or hypertension and were less likely to report being physically active or consuming a healthy diet.
Patients were more likely to choose more intensive care after an annual consultation if they had a high level of education, if they were concerned about illness, if they had set goals for their care, and if they had comorbid conditions.
The industry-funded PIONEER 3 trial randomized adults whose type 2 diabetes was uncontrolled with metformin, with or without sulfonylurea, to receive either oral sitagliptin (100 mg/d) or oral semaglutide (3, 7, or 14 mg/d).